Despite some limitations, the expression of PD‐L1 by immunohistochemistry (IHC) is advanced as a predictive biomarker for anti‐PD‐1 therapy in non‐small‐cell lung cancer and some other tumor types, and continues to be explored in the context of MSI tumors.15 This evidence concerns the gene CD274 and neoplasm.